Safety and Tolerability of Monoclonal Antibody Therapies for Treatment of COVID-19 in Pediatric Patients
| Autor: | Aimee M Dassner, Benjamin Hanisch, Gregory Mak, Benjamin M Hammer |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Microbiology (medical)
2019-20 coronavirus outbreak medicine.medical_specialty Adolescent Coronavirus disease 2019 (COVID-19) medicine.drug_class MEDLINE Severe disease Antibodies Monoclonal Humanized Monoclonal antibody Antiviral Agents Young Adult Internal medicine Humans Medicine Child Monoclonal antibody therapy Retrospective Studies SARS-CoV-2 business.industry Antibodies Monoclonal COVID-19 Retrospective cohort study Antibodies Neutralizing Drug Combinations Infectious Diseases Tolerability Pediatrics Perinatology and Child Health business |
| Zdroj: | Pediatric Infectious Disease Journal. 40:e507-e509 |
| ISSN: | 0891-3668 |
| DOI: | 10.1097/inf.0000000000003263 |
| Popis: | There is a little data regarding safety or efficacy of monoclonal antibody treatment for mild-to-moderate COVID-19 in pediatric patients despite it being frequently used in adults. This retrospective study of 17 patients with mild-to-moderate COVID-19 who received monoclonal antibody therapy found that the treatment was well tolerated, safe, and may be effective in halting progression to severe disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|